CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The CARESS project aims to develop a compact and affordable system for measuring Dihydropyrimidine dehydrogenase activity in patients undergoing 5-FU chemotherapy. This technology will enable rapid screening for genetic variations that affect drug metabolism, allowing for personalized treatment adjustments to enhance e…
Amongst all the chemotherapy agents, 5-FU (fluorouracil) is being in use since 40 years, and is one of the most successful and widely employed in the treatment for breast, colon, and skin cancer, three of the most frequently occurring malignant tumours.
In general, 5-FU is relatively well tolerated at standard doses, but there are some important issues that must be duly taken into consideration: 1)Around 8% of patients manifest a genetic variation that leads to a deficiency of an enzyme called D…
IRBM SPA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, ANGERS
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
France, Saint Marcel Paulel
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Austria, Graz
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
